Cambridge, England, United Kingdom, July 2024 – Becky Eretta has started her new role as Head of Human Resources at Alchemab Therapeutics Ltd. In this position, Becky will be responsible for leading the HR strategy and initiatives to support the company’s growth and employee engagement.
Becky Eretta brings extensive experience in human resources, having held various leadership roles in the industry. Before joining Alchemab Therapeutics, she served as the Human Resources Director at the same company, where she implemented effective HR policies and fostered a positive workplace culture.
Prior to Alchemab, Becky worked at Silence Therapeutics plc as the Director of HR, Europe and Associate Director, HR, where she led HR operations and strategic initiatives across Europe. Her brief stint at atai Life Sciences as an Associate Director, HR Business Partner showcased her ability to manage HR functions in a dynamic environment.
Becky’s career includes roles such as an Independent Human Resources Consultant for Silence Therapeutics plc, Director at EVE HR Consulting Limited, and Associate Director – HR at EUSA Pharma. Her experience at EUSA Pharma included roles as Regional EU HR Manager, demonstrating her expertise in managing HR operations across multiple regions.
Earlier in her career, Becky held positions such as Group Human Resources Manager at The Chesterford Group, Human Resources Business Partner at Graydon UK, People Business Partner at Pearson plc, and HR Advisor at Eisai EMEA. She began her HR journey at Computacenter as an HR Advisor and HR/Payroll Administrator at Octavian.
About Alchemab Therapeutics Ltd:
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat diseases in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom they partner to further their understanding of disease.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
